natgillin/translations-raw huggingface dataset:
Brug én oral sprøjte til alle doserne samme dag. 
Use one oral syringe for all doses taken each day.
RAVICTI skal bruges med proteinrestriktion i kosten og undertiden kosttilskud (f.eks. essentielle aminosyrer, arginin, citrullin, proteinfrit kalorietilskud) afhængigt af, hvor stor en daglige indtagelse af protein i kosten der skal til for at fremme vækst og udvikling. 
RAVICTI must be used with dietary protein restriction and sometimes dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements) depending on the daily dietary protein intake needed to promote growth and development.
Vend flasken på hovedet med den orale sprøjte siddende i. Fyld sprøjten ved at trække stemplet tilbage, indtil sprøjten er fyldt med den ønskede mængde lægemiddel. 
Fill the oral syringe by pulling the plunger back until the syringe is filled with the amount of medicinal product.
RAVICTIs udseende og pakningsstørrelser 
What RAVICTI looks like and contents of the pack
Tre patienter var behandlingsnaive, og hos tre yderligere patienter blev intravenøs natriumbenzoat og natriumphenylacetat gradvist seponeret, mens RAVICTI blev påbegyndt. 
Three patients were treatment naïve and three additional patients were gradually discontinued from intravenous sodium benzoate and sodium phenylacetate while RAVICTI was initiated.
• 8,5 ml/m2/dag (9,4 g/m2/dag) hos patienter med kropsoverfladeareal (BSA) < 1,3 m2 
• 8.5 ml/m2/day (9.4 g/m2/day) in patients with a body surface area (BSA) < 1.3 m2
• Trin 2: 50 % dosis af natriumphenylacetat/natriumbenzoat og 100 % RAVICTI i 4-8 timer 
• Step 2: 50% dose sodium phenylacetate/sodium benzoate and 100% RAVICTI for 4-8 hours;
Kemisk kompatibilitet af glycerolphenylbutyrat med nasogastriske, nasojejunale eller gastrostomisonder af silikone af medicinsk kvalitet er blevet påvist. 
Chemical compatibility of glycerol phenylbutyrate with medical grade silicone nasogastric, gastrostomy, and nasojejunal tubes has been demonstrated.
Glycerolphenylbutyrat var non-inferiort i forhold til natriumphenylbutyrat med hensyn til AUC0-24t for ammoniak. 
Glycerol phenylbutyrate was non-inferior to sodium phenylbutyrate with respect to the 24-hour AUC for ammonia.
Høje niveauer af ammoniak forårsager kvalme, opkastning eller forvirring. 
High levels of ammonia leads to feeling sick (nausea), being sick (vomiting) or feeling confused.
Når patienter, som skifter fra natriumphenylacetat/natriumbenzoat til RAVICTI, er stabile med kontrolleret ammoniak bør de få en dosis RAVICTI i den højere ende af behandlingsområdet (11,2 ml/m2/dag) med måling af ammoniak i plasma som vejledning for yderligere dosering. 
Initial dosage in patients switching from sodium phenylacetate/sodium benzoate injection to RAVICTI: Once stable with controlled ammonia, patients switching from sodium phenylacetate/sodium benzoate to RAVICTI should receive a dose of RAVICTI at the higher end of the treatment range (11.2 ml/m2/day) with measurements of plasma ammonia to guide further dosing.
In vitro blev 80,6 % til 98,0 % af 14C-mærkede metabolitter af PBA (i intervallet 1-250 mikrogram/ml) bundet til plasmaprotein, og 37,1 % til 65,6 % af 14C-mærkede metabolitter af PAA (i intervallet 5-500 mikrogram/ml). 
In vitro, the extent of human plasma protein binding for 14C-labeled metabolites was 80.6% to 98.0% for PBA (over 1-250 microgram/ml), and 37.1% to 65.6% for PAA (over 5-500 microgram /ml).
Ud af 49 pædiatriske patienter, som deltog i disse forlængelsesforsøg, rapporterede 12 patienter (25 %) i alt 17 hyperammoniæmiske kriser under behandling med glycerolphenylbutyrat sammenlignet med 38 kriser hos 21 patienter (43 %) under behandling med natriumphenylbutyrat i de 12 måneder forud for studieinklusion. 
Of the 49 paediatric patients who participated in these extension studies, 12 patients (25 %) reported a total of 17 hyperammonaemic crises during treatment with glycerol phenylbutyrate as compared with 38 crises in 21 patients (43 %) in the preceding 12 months prior to study entry, while they were being treated with sodium phenylbutyrate.
Glycerolphenylbutyrat hydrolyseres af pancreaslipaser til PBA, som ved beta-oxidation omdannes til PAA, den aktive del af glycerolphenylbutyrat. 
Glycerol phenylbutyrate is hydrolysed by pancreatic lipases to yield, PBA, which is converted by beta oxidation to PAA, the active moiety of glycerol phenylbutyrate.
Den daglige dosis skal justeres individuelt i henhold til patientens proteintolerance og den daglige mængde protein, der er behov for at indtage gennem kosten. 
The daily dose should be individually adjusted according to the patient's protein tolerance and the daily dietary protein intake needed.
Studie med børn i alderen 2 måneder til under 2 år I alt 10 pædiatriske patienter med UCD'er i alderen 2 måneder til under 2 år deltog i et langtids(24 måneder), ukontrolleret, åbent studie, hvoraf 6 patienter konverterede fra natriumphenylbutyrat til RAVICTI, og 1 patient konverterede fra natriumphenylbutyrat og natriumbenzoat. 
Study in Children 2 Months to Less than 2 Years of Age A total of 10 paediatric patients with UCDs aged 2 months to less than 2 years participated in a long term (24 months) uncontrolled, open label study, of which 6 patients converted from sodium phenylbutyrate to RAVICTI and 1 patient converted from sodium phenylbutyrate and sodium benzoate.
I et studie hos patienter med klinisk dekompenseret cirrose og hepatisk encefalopati (Child-Pugh B og C), var den gennemsnitlige Cmax af PAA 144 mikrogram/ml (14-358 mikrogram/ml) efter en daglig dosis på 6 ml glycerolphenylbutyrat to gange dagligt, og den gennemsnitlige Cmax af PAA var 292 mikrogram/ml (57-655 mikrogram/ml) efter en daglig dosis på 9 ml glycerolphenylbutyrat to gange dagligt. 
In a study in patients with clinically decompensated cirrhosis and hepatic encephalopathy (Child-Pugh B and C), mean Cmax of PAA was 144 mcg/ml (range: 14-358 mcg /ml) after daily dosing of 6 ml of glycerol phenylbutyrate twice daily, while mean Cmax of PAA was 292 mcg /ml (range: 57-655 mcg/ml) after daily dosing of 9 ml of glycerol phenylbutyrate twice daily.
I alt 49 børn i alderen fra 2 måneder til 17 år med defekter i OTC, ASS, ASL og ARG blev inkluderet, og alle med undtagelse af 1 var blevet omstillet fra natriumphenylbutyrat til glycerolphenylbutyrat. 
A total of 49 children ages 2 months to 17 years with deficiencies of OTC, ASS, ASL, and ARG were enrolled, and all but 1 had been converted from sodium phenylbutyrate to glycerol phenylbutyrate.
Monitorer ammoniakniveauet nøje, når det er nødvendigt at behandle UCD-patienter med valproinsyre eller haloperidol. 
Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in UCD patients.
Samtidig brug af lægemidler, der vides at hæmme lipase, skal gives med forsigtighed, da glycerolphenylbutyrat hydrolyseres til phenylbutansyre og glycerol af fordøjelsesenzymet lipase. 
Concomitant use of medicinal products known to inhibit lipase should be given with caution as glycerol phenylbutyrate is hydrolysed by digestive lipase into phenylbutyrate acid and glycerol.
Ud af 51 voksne patienter, som deltog i studie 2, rapporterede 7 patienter (14 %) i alt 10 hyperammoniæmiske kriser under behandling med glycerolphenylbutyrat sammenlignet med 9 patienter (18 %), som havde rapporteret i alt 15 kriser under behandling med natriumphenylbutyrat i de 12 måneder forud for studieinklusion. 
Of 51 adult patients participating in Study 2, 7 patients (14%) reported a total of 10 hyperammonaemic crises during treatment with glycerol phenylbutyrate as compared with 9 patients (18 %) who had reported a total of 15 crises in the 12 months prior to study entry while they were being treated with sodium phenylbutyrate.
Reduceret absorption af phenylbutyrat ved pancreasinsufficiens eller intestinal malabsorption Eksokrine pancreasenzymer hydrolyserer glycerolphenylbutyrat i tyndtarmen og spalter den aktive del, phenylbutyrat, fra glycerol. 
Reduced phenylbutyrate absorption in pancreatic insufficiency or intestinal malabsorption Exocrine pancreatic enzymes hydrolyse glycerol phenylbutyrate in the small intestine, separating the active moiety, phenylbutyrate, from glycerol.
• kortikosteroider - anvendes til behandling af inflammation (betændelseslignende tilstande) i kroppen 
• corticosteroids - used to treat inflamed areas of the body
Farmakologisk virkning 
Pharmacological effects
For at undgå at der kommer vand i lægemidlet, skal sprøjten der bruges til at gennemskylle gastrostomisonden eller den nasogastriske sonde ikke bruges til afmåling af doser af RAVICTI. 
The syringe used to flush the gastrostomy or nasogastric tube shall not be used for measuring the dose of RAVICTI to avoid introduction of water into the medicinal product.
De gennemsnitlige glutaminniveauer i blodet var ligeledes ikke-signifikant lavere efter behandling med glycerolphenylbutyrat sammenlignet med natriumphenylbutyrat med -45,2 ± 142,94 mikromol/l (p = 0,135, parret t-test; p = 0,114, Wilcoxon-test). 
Mean blood glutamine levels were also non-significantly lower after glycerol phenylbutyrate treatment compared with sodium phenylbutyrate treatment by -45.2 ± 142.94 micromol/L (p = 0.135, paired ttest; p = 0.114, Wilcoxon signed-rank test).
RAVICTI-pakningen indeholder lægemidlet og en genlukkelig lågadapter. 
The RAVICTI pack contains the medicinal product and a reclosable bottle cap adapter.
Vigtigt: Bland ikke RAVICTI med større mængder væske, såsom vand eller juice, da vand forårsager nedbrydning af glycerolphenylbutyrat. 
Important note: Do not add or stir RAVICTI into larger volumes of liquid such as water or juice as the introduction of water causes glycerol phenylbutyrate to degrade.
• Samlet daglig dosis RAVICTI (ml) = samlet daglig dosis natriumphenylbutyrat-pulver (g) x 
• Total daily dosage of RAVICTI (ml) = total daily dosage of sodium phenylbutyrate powder (g) x 0.81
Et langvarigt (12-måneders), ukontrolleret åbent studie (studie 2) blev udført for at vurdere månedlig ammoniakkontrol og hyperammoniæmisk krise i løbet af en periode på 12 måneder. 
Open-Label Uncontrolled Extension Study in Adults A long-term (12-month), uncontrolled, open-label study (Study 2) was conducted to assess monthly ammonia control and hyperammonaemic crisis over a 12-month period.
Den anbefalede dosis til patienter, som ikke tidligere er blevet behandlet med phenylbutansyre, og til patienter, som skifter fra natriumphenylbutyrat eller fra injektion med natriumphenylacetat/natriumbenzoat til RAVICTI, er forskellig. 
The recommended dosages for patients naïve to phenylbutyric acid and for patients switching from sodium phenylbutyrate or from sodium phenylacetate/sodium benzoate injection to RAVICTI are different.
• menstruationer stopper eller er uregelmæssige, hæs stemme, næseblod, tilstoppet næse, øm hals eller ondt i halsen, hårtab, svedtendens, kløende udslæt, uregelmæssige hjerteslag (puls), nedsat funktion af skjoldbruskkirtlen 
• menstrual periods stop or are irregular, hoarse voice, nosebleeds, stuffy nose, sore or painful throat, hair loss, sweating more than usual, itchy rash, uneven heartbeat, reduced thyroid function
• tilbageløb af maveindhold 
• reflux of stomach contents
Overensstemmende med ammoniak i plasma var glutamin-niveauet i blodet lavere under behandling med glycerolphenylbutyrat sammenlignet med natriumphenylbutyrat i hver behandlingsgruppe i overkrydsningsforsøget (reduktion på 44,3 ± 154,43 mikromol/l efter glycerolphenylbutyrat sammenlignet med natriumphenylbutyrat; p = 0,064, parret t-test; p = 0,048, Wilcoxon-test). 
Consistent with plasma ammonia, blood glutamine levels were lower during glycerol phenylbutyrate treatment as compared with sodium phenylbutyrate in each arm of the crossover study (decrease of 44.3 ± 154.43 micromol/L after glycerol phenylbutyrate compared with NaPBA; p = 0.064, paired t-test; p = 0.048, Wilcoxon signed-rank test).
Patienterne skal adviseres om at anskaffe CE-mærkede orale sprøjter af en størrelse, der passer til den ordinerede dosis og som er kompatible med den genlukkelige lågadapter, fra apoteket. 
Based on prescribed dosing volume, patients should be advised to obtain CE marked oral syringes with suitable size for the dosage and compatible with the reclosable bottle cap adapter from the pharmacy.
• Trin 3: seponering af natriumphenylacetat/natriumbenzoat og fuld dosis af RAVICTI 
• Step 3: sodium phenylacetate/sodium benzoate discontinued and full dose RAVICTI
Glycerolphenylbutyrat havde ingen indvirkning på fertilitet eller reproduktion hos han- og hunrotter (se pkt. 
Glycerol phenylbutyrate had no effect on fertility or reproductive function in male and female rats (see section 5.3).
I et separat studie hos patienter med nedsat leverfunktion (Child-Pugh B og C) var ratioen mellem middelværdierne af PAA og PAGN mellem 0,96 og 1,28 for alle patienter, som fik en dosis på 6 ml og 9 ml to gange dagligt, og mellem 1,18 og 3,19 for patienter, som fik 9 ml to gange dagligt. 
In a separate study, in patients with hepatic impairment (Child-Pugh B and C), the ratios of mean values for PAA to PAGN among all patients dosed with 6 ml and 9 ml twice daily ranged from 0.96 to 1.28 and for patients dosed with 9 ml twice daily ranged from 1.18-3.19.
Sæt omhyggeligt den tøjrede hætte på adapteren efter brug. 
Tightly close the tethered tab on the reclosable bottle adapter after use.
To patienter var behandlingsnaive og hos 1 yderligere patient blev intravenøs natriumbenzoat og natriumphenylacetat gradvist seponeret, mens RAVICTI blev påbegyndt. 
Two patients were treatment naïve and one additional patient was gradually discontinued from intravenous sodium benzoate and sodium phenylacetate while RAVICTI was initiated.
• præventionsmidler 
• contraceptives
Forstoppelse Diarré 
Constipation Diarrhoea
• desorientering 
• feeling disorientated
Påvirkning af fertilitet 
Impairment of fertility
CE-mærkede orale sprøjter kompatible med den genlukkelige lågadapter kan fås på apoteket. 
CE marked oral syringes compatible with the reclosable bottle cap adapter can be obtained from a pharmacy.
Ikke almindelig Forhøjet kalium i blodet, forhøjede triglycerider i blodet, unormalt elektrokardiogram, forhøjet low density lipoprotein, forlænget protrombintid, forhøjet leukocyttælling, vægtstigning, vægttab 
Increased aspartate aminotransferase, alanine aminotransferase increased, increased anion gap, decreased lymphocyte count, decreased vitamin D Uncommon Blood potassium increased, blood triglycerides increased, electrocardiogram abnormal, low density lipoprotein increased, prothrombin time prolonged, white blood cell count increased, weight increased, weight decreased
• lipase-hæmmere - anvendes til at behandle fedme 
• lipase inhibitors - used to treat obesity
Der blev ikke detekteret uomdannet glycerolphenylbutyrat i plasma hos UCDpatienter. 
Intact glycerol phenylbutyrate was not detectable in plasma in UCD patients.
Plasma-PAA:PAGN-ratioen kan være nyttig ved dosisovervågning (se pkt. 
The plasma PAA to PAGN ratio may be useful in dosage monitoring.
Efter oral indtagelse frigøres PBA fra glycerol-skelettet i mavetarm-kanalen af pancreaslipaser. 
Upon oral ingestion, PBA is released from the glycerol backbone in the gastrointestinal tract by pancreatic lipases.
PAA, den aktive metabolit af glycerolphenylbutyrat, er forbundet med tegn og symptomer på neurotoksicitet (se pkt. 
PAA, the active metabolite of glycerol phenylbutyrate, is associated with signs and symptoms of neurotoxicity (see section 4.4) and could accumulate in patients who receive an overdose.
Drej den lukbare adapter på flasken. 
Twist the reclosable bottle cap adapter onto the bottle.
1 lukbar adapter 
1 reclosable bottle cap adapter.
For at sikre korrekt dosering af RAVICTI kan du på apoteket købe CE-mærkede orale sprøjter i en størrelse, der passer til din dosis, og som er kompatible med den lukbare adaptor til flaskelåget. 
In order to ensure correct dosing of RAVICTI, CE-marked oral syringes with suitable size for the dosage and compatible with the reclosable bottle cap adapter can be obtained from the pharmacy.
Kliniske studier hos pædiatriske patienter med UCD'er Virkningen af glycerolphenylbutyrat hos pædiatriske patienter i alderen fra 2 måneder til 17 år, som havde defekter i OTC, ASS, ASL eller ARG, blev evalueret i 2 åbne studier med fastlagt rækkefølge og skift fra natriumphenylbutyrat til ækvivalent dosis glycerolphenylbutyrat (studie 3 og 4). 
The efficacy of glycerol phenylbutyrate in paediatric patients 2 months to 17 years of age involving deficiencies of OTC, ASS, ASL, and ARG was evaluated in 2 fixed sequence, open-label, sodium phenylbutyrate to equivalent dosing of glycerol phenylbutyrate switchover studies (Studies 3 and 4).
Udslæt Bivirkninger hos patienter i alderen 2 måneder til under 2 år 
ADRs in patients 2 months to less than 2 years of age
Adapteren bruges, indtil flasken er tom. 
The reclosable bottle cap adapter can be used until the bottle is empty.
Valproinsyre og haloperidol kan inducere hyperammoniæmi. 
Hyperammonemia may be induced by haloperidol and by valproic acid.
• oppustethed eller mavesmerter, forstoppelse, diarré, halsbrand, luft i maven, kvalme, smerter i munden, opkastningsfornemmelser 
• stomach bloating or pain, constipation, diarrhoea, heartburn, wind, feeling sick (nausea), pain in the mouth, retching
Den daglige dosis skal justeres individuelt i henhold til patientens estimerede urinstofsyntesekapacitet, om nogen, aminosyreprofil, proteintolerance og den daglige proteinindtagelse gennem kosten, som er nødvendig for at fremme vækst og udvikling. 
The daily dose should be individually adjusted according to the patient's estimated urea synthetic capacity, if any, amino acid profile, protein tolerance and the daily dietary protein intake needed to promote growth and development.
Almindelig Unormal lugt fra huden, acne Ikke almindelig Alopeci, hyperhidrose, kløende udslæt 
Abnormal skin odour, acne Uncommon Alopecia, hyperhidrosis, pruritic rash
Elektrofysiologisk påvirkning af hjertet 
Cardiac electrophysiology
• 7.000 mikrogram/ml for patienter >2 år med BSA ≤1,3 
• 7000 microgram (mcg/ml) for patients >2 years of age with a BSA of ≤1.3
Kvinder i den fertile alder/kontraception hos mænd og kvinder Kvinder i den fertile alder skal anvende sikker kontraception (se pkt. 
Women of childbearing potential/contraception in males and females Effective contraceptive measures must be taken by women of child-bearing potential (see section 4.6).
• 5.000 mikrogram/ml for patienter >2 år med BSA >1,3 
• 5000 microgram (mcg/ml) for patients >2 years of age with a BSA of >1.3
Gennemsnitlige 24-timers-AUC'er for venøs ammoniak ved steady state dosering var 866 mikromol/l•time og 977 mikromol/l•time for hhv. glycerolphenylbutyrat og natriumphenylbutyrat (n = 44, forhold mellem de geometriske middelværdier 0,91; 95 % konfidensinterval 0,799; 1,034). 
Mean 24-hour AUCs for venous ammonia during steady-state dosing were 866 micromol/L*hour and 977 micromol/L*hour with glycerol phenylbutyrate and sodium phenylbutyrate, respectively (n = 44, ratio of geometric means 0.91; 95% confidence intervals 0.799, 1.034).
Ikke almindelig Abdominalt ubehag, unormal afføring, mundtørhed, ructus, afføringstrang, smerter i øvre og/eller nedre abdomen, smerter ved afføring, steatoré, stomatitis 
Uncommon Abdominal discomfort, abnormal faeces, dry mouth, eructation, defaecation urgency, upper abdominal pain and/or lower abdominal pain, painful defaecation, steatorrhoea, stomatitis
Om urinstofcyklus-defekter 
About urea cycle disorders
I den puljede analyse af forsøg, hvor patienter skiftede fra natriumphenylbutyrat til glycerolphenylbutyrat, var ammoniak-AUC0-24t 774,11 og 991,19 [(mikromol/l)•time] ved behandling med hhv. glycerolphenylbutyrat og natriumphenylbutyrat (n = 80, forhold mellem de geometriske middelværdier 0,84; 95 % konfidensinterval 0,740; 0,949). 
In the pooled analysis of studies where patients switched from sodium phenylbutyrate to glycerol phenylbutyrate, ammonia AUC0-24h was 774.11 and 991.19 [(micromol/L)*hour] during treatment with glycerol phenylbutyrate and sodium phenylbutyrate, respectively (n = 80, ratio of geometric means 0.84; 95% confidence intervals 0.740, 0.949).
I den puljede analyse af de kortvarige studier med børn (studie 3 og studie 4) var plasma-ammoniak signifikant lavere efter skift til glycerolphenylbutyrat; ammoniak AUC0-24t var 626,79 og 871,72 (mikromol/l)∙time under behandling med hhv. glycerolphenylbutyrat og natriumphenylbutyrat (n = 26, forhold mellem de geometriske middelværdier 0,79; 95 % konfidensinterval 0,647, 0,955). 
In the pooled analysis of the short-term studies in children (Study 3 and Study 4), plasma ammonia was significantly lower after switching to glycerol phenylbutyrate; ammonia AUC0-24h was 626.79 and 871.72 (micromol/L)*hour during treatment with glycerol phenylbutyrate and sodium phenylbutyrate, respectively (n = 26, ratio of geometric means 0.79; 95% confidence intervals 0.647, 0.955).
• Trin 1: 100 % dosis af natriumphenylacetat/natriumbenzoat og 50 % dosis af RAVICTI i 
• Step 1: 100% dose sodium phenylacetate/sodium benzoate and 50% dose of RAVICTI for 4-8
• galdeblære-, blære- eller rygsmerter 
• gallbladder, bladder or back pain
Sådan skal du tage RAVICTI 
How to take RAVICTI
Almindelig Flatulens, diarré, opkastning, kvalme, abdominalsmerter, dyspepsi, oppustethed, forstoppelse, orale gener, opkastningsfornemmelse 
Flatulence, diarrhoea, vomiting, nausea, abdominal pain, dyspepsia, abdominal distension, constipation, oral discomfort, retching
Anbring spidsen af den orale sprøjte i adapteren. 
Place the tip of the oral syringe into the reclosable bottle cap adapter.
Den daglige dosis skal justeres individuelt i henhold til den skønnede kapacitet af patientens urinstofsyntese, om nogen, patientens proteintolerance samt den daglige proteinindtagelse, som er nødvendig for patientens vækst og udvikling. 
The daily dose should be individually adjusted according to the patient's estimated urea synthetic capacity, if any, protein tolerance and the daily dietary protein intake needed to promote growth and development.
En ny adapter skal anvendes, hver gang en ny flaske åbnes. 
A new reclosable bottle cap adapter should be used for each new bottle that is opened.
Luftveje, thorax og mediastinum 
Respiratory, thoracic and mediastinal disorder
Almindelig Svimmelhed, hovedpine, tremor Ikke almindelig Dysgeusi, letargi, paræstesi, psykomotorisk hyperaktivitet, døsighed, taleforstyrrelse Ikke almindelig Konfusion, sænket stemningsleje 
Dizziness, headache, tremor Uncommon Dysgeusia, lethargy, paraesthesia, psychomotor hyperactivity, somnolence, speech disorder
Hvis du har glemt at tage en dosis, skal du tage den glemte dosis, så snart du husker det. For voksne gælder, at hvis den næste dosis er om mindre end 2 timer, skal du springe den over og tage den næste dosis som normalt. 
However, for adults, if the next dose is in less than 2 hours, then skip it and take your next dose as normal.
- Denne kostplan vil blive sammensat til dig af din læge og diætist. 
RAVICTI must be used with a special low protein diet. - This diet will be designed for you by your doctor and dietician.
• bøvsen, mavesmerter, ændringer i afføringen såsom olieret afføring, afføringstrang, smerter ved afføring 
• burping, stomach ache, changes in your stools such as being oily, urgent need for bowel movements, painful bowel movements
Hvis U-PAGN-udskillelsen er utilstrækkelig til at redegøre for den daglige proteinindtagelse i kosten, og det fastende ammoniakniveau er højere end halvdelen af anbefalet ULN, skal glycerolphenylbutyrat-dosen justeres op. Ved dosisjustering skal der tages hensyn til mængden af protein i kosten, som ikke er blevet dækket, angivet som U-PAGN-niveauet over et døgn, samt den estimerede nødvendige dosis glycerolphenylbutyrat pr. gram protein i kosten. 
If U-PAGN excretion is insufficient to cover daily dietary protein intake and the fasting ammonia is greater than half the recommended ULN, the glycerol phenylbutyrate dose should be adjusted upward.
• Administrér lægemidlet ved at bruge stemplet i den orale sprøjte til at sprøjte RAVICTI ind i sonden. 
• Utilising the plunger of the oral syringe, administer RAVICTI into the tube.